Obesity has increased in prevalence worldwide and WHO has declared it a global epidemic.
Population-level preventive interventions have been insufficient to slow down this trajectory …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

The burden of heart failure among people with type 2 diabetes is increasing globally. People
with comorbid type 2 diabetes and heart failure often have worse outcomes than those with …

Major updates to 1991 National Institutes of Health guidelines for bariatric surgery Metabolic
and bariatric surgery (MBS) is recommended for individuals with a body mass index (BMI)> …

Objective The aim of this study was to compare the effectiveness of semaglutide versus
liraglutide for treating post‐metabolic and bariatric surgery (MBS) weight recurrence …

Background Patients with overweight and obesity are at increased risk of death from multiple
causes, including cardiovascular (CV) death, with few therapies proven to reduce the risk …

The prevalence of obesity continues to rise around the world, driving up the need for
effective and durable treatments. The field of metabolic/bariatric surgery has grown rapidly in …

Currently, metabolic surgery (MS) constitutes the most effective means for durable weight
loss of clinically meaningful magnitude, type 2 diabetes remission and resolution of non …

Many unique clinical challenges accompany the diagnosis and treatment of cardiovascular
disease (CVD) in people living with overweight/obesity. Similarly, physicians encounter …

Obesity is a major public health problem that is associated with serious comorbidities and
premature mortality. Cardiovascular disease (CVD) is the major cause of morbidity and …